Skip to content

Trombocytopathy in the Netherlands

Trombocytopathy in the Netherlands

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON22771
Enrollment
150
Registered
2016-08-05
Start date
2016-02-11
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platelet function disorders Trombocytopathie

Interventions

None

Sponsors

UMC Utrecht
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Age > 18 years - History of bleeding diathesis suspected for a PFD

Exclusion criteria

Exclusion criteria: - Inability to give informed consent - Bleeding diathesis due to an acquired PFD, von Willebrand disease, hemophilia or other disorders of secondary hemostasis or fibrinolysis - Current use of antiplatelet therapy

Design outcomes

Primary

MeasureTime frame
- Frequency and severity of bleeding symptoms: bleeding score using the ISTH-BAT - Treatment of bleeding diathesis: type and frequency of treatment received in the past (local treatment, antifibrinolytics, DDAVP, platelet transfusion) - Impact of PFD on quality of life: RAND-36 health survey score

Secondary

MeasureTime frame
- Diagnostic utility of additional platelet tests as compared to standard LTA - Relation between type of PFD and bleeding phenotype - Genotype-phenotype relationship

Contacts

Public ContactMaaike Blaauwgeers

Van Creveldkliniek UMC Utrecht - huispost C01.425

m.w.blaauwgeers@umcutrecht.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)